Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Read on to find out more.
Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on designing, developing and commercializing products for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that it has entered into a lease agreement for approximately 19,700 additional square feet to its existing premises in Plymouth, MN.
The Company is expected to be in possession of the additional space beginning in February 2016. The Company’s lease of the Plymouth facility has a term expiring in June 2021, with an option to extend the term for an additional three years.
“We expect this additional space will enable us to meet the needs of our rapidly expanding business and continue to lead in customer-focused innovation and training. Our ability to educate physicians, train our growing sales force and increase our R&D footprint were central in the decision to expand,” said Robert White, President and Chief Executive Officer. “We are pleased to expand our Plymouth facility to accommodate our growing business needs.”
Entellus Medical is a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room. Its XprESS family of products is used by ENT physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. When used as a stand-alone therapy, Entellus Medical’s balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery, or FESS.
Patients treated with Entellus Medical’s products in this trial in the ENT physician’s office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS. Entellus Medical currently markets its products in the United States, Europe and Canada and sells its products through a direct sales force in the United States and the UK.
